Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byCubist Pharmaceuticals
Price$92.5M
Date12/2009
TermsCash

General Information

Websitecalixainc.com
CategoryBioTech
Phone(858) 480-2420
Emailinformation@calix...
Employees

Offices

San Mateo, USA
1840 Gateway Drive
Suite 200
San Mateo, CA, 94404
USA

People

Executive Vice President and CSO
Chief Medical Officer

Tags

Calixa Therapeutics

Calixa Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of a novel cephalosporin to address the expanding problem of multi-drug resistant organisms. Treatment of infections caused by resistant gram-negative bacteria, especially Pseudomonas aeruginosa, is recognized as an unmet medical need by the infectious diseases community.

Calixa’s lead product, CXA-101, is an IV formulation of a novel cephalosporin that has excellent potency especially against multi-drug resistant Pseudomonas aeruginosa, which differentiates it from other cephalosporins. No similar drug is known to be in development. Calixa plans to combine this product with a β-lactamase inhibitor; the combination product (CXA-201) has the potential to become the first-line therapeutic choice for hospitalized patients suffering from serious infection caused by gram-negative organisms.

Recent Milestones

Videos

Screenshots

Calixa Therapeutics screenshot
Above: Home Page
Uploaded: 12/15/09

Sources

  1. Cubist buying Calixa Therapeutics for up to $402.5M (masshightech.com) [edit]
Edit This Page
Last Edited 3/4/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy